IL17A and psoriasis: Real-life studies highlight the clinical benefits of these drugs in different populations [54] and provide evidence that even a change from IL−17 inhibitors to TNF-α or IL−12/23 inhibitors can be a safe and effective therapeutic strategy for long lasting psoriasis [55].